A detailed history of Amalgamated Bank transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 3,072 shares of RLAY stock, worth $19,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,072
Previous 8,201 62.54%
Holding current value
$19,537
Previous $90,000 72.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$7.5 - $12.07 $38,467 - $61,907
-5,129 Reduced 62.54%
3,072 $25,000
Q4 2023

Feb 06, 2024

SELL
$6.01 - $11.48 $5,493 - $10,492
-914 Reduced 10.03%
8,201 $90,000
Q3 2023

Nov 08, 2023

BUY
$8.24 - $12.97 $4,597 - $7,237
558 Added 6.52%
9,115 $77,000
Q2 2023

Aug 11, 2023

SELL
$9.99 - $18.27 $6,503 - $11,893
-651 Reduced 7.07%
8,557 $107,000
Q1 2023

May 02, 2023

SELL
$15.0 - $22.76 $31,710 - $48,114
-2,114 Reduced 18.67%
9,208 $152,000
Q4 2022

Feb 10, 2023

BUY
$14.16 - $24.02 $18,917 - $32,090
1,336 Added 13.38%
11,322 $169,000
Q3 2022

Nov 09, 2022

BUY
$18.07 - $31.37 $1,843 - $3,199
102 Added 1.03%
9,986 $223,000
Q2 2022

Aug 15, 2022

SELL
$13.31 - $34.88 $16,011 - $41,960
-1,203 Reduced 10.85%
9,884 $166,000
Q1 2022

Jun 30, 2022

SELL
$20.26 - $32.36 $16,775 - $26,794
-828 Reduced 6.95%
11,087 $332,000
Q4 2021

Feb 15, 2022

BUY
$26.0 - $37.03 $40,404 - $57,544
1,554 Added 15.0%
11,915 $366,000
Q3 2021

Oct 29, 2021

SELL
$29.75 - $37.99 $11,543 - $14,740
-388 Reduced 3.61%
10,361 $327,000
Q2 2021

Aug 16, 2021

BUY
$27.5 - $38.19 $133,842 - $185,870
4,867 Added 82.74%
10,749 $393,000
Q1 2021

May 13, 2021

BUY
$32.52 - $61.53 $191,282 - $361,919
5,882 New
5,882 $203,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.